Register Login

Alnylam Pharmaceuticals Inc (ALNY)

(10% Negative) Alnylam Pharmaceuticals Inc (ALNY) Announces Delay in leadership Trials for AMVUTTRA Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 30, 2026, 8:17 a.m.

    📋 Alnylam Pharmaceuticals Inc (ALNY) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:30:20

    Event Type: Clinical Trial Update

    Event Details:

    Alnylam Pharmaceuticals Inc (ALNY) Announces Clinical Trial Update Alnylam Pharmaceuticals Inc (ALNY) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: leadership, revenues
    • Diseases/Conditions: AMVUTTRA, ATTR amyloidosis
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Media
    • Updated Timeline: fourth quarter and full year 2025, Year 2025

    🔬 Clinical Development Pipeline (Alnylam Pharmaceuticals Inc):

    Product Type Development Stage Therapeutic Area Source
    ALN-4324 DRUG Phase PHASE1 Obese or Overweight Healthy Volunteers ClinicalTrials.gov
    ALN-HTT02 DRUG Phase PHASE1 Huntington's Disease ClinicalTrials.gov
    ALN-6400 DRUG Phase PHASE1 Hereditary Hemorrhagic Telangiectasia ClinicalTrials.gov
    Zilebesiran DRUG Phase PHASE3 High Risk Cardiovascular Disease ClinicalTrials.gov
    patisiran DRUG Phase EARLY_PHASE1 Polyneuropathies ClinicalTrials.gov
    Vutrisiran DRUG Phase PHASE3 Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy ClinicalTrials.gov
    Nucresiran DRUG Phase PHASE3 Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Transthyretin Amyloidosis (ATTR) With Cardiomyopathy ClinicalTrials.gov
    Sterile Normal Saline (0.9% NaCl) DRUG Phase PHASE3 Transthyretin Amyloidosis (ATTR) With Cardiomyopathy ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE1 Advanced Hepatocellular Carcinoma ClinicalTrials.gov
    ALN-BCAT DRUG Phase PHASE1 Advanced Hepatocellular Carcinoma ClinicalTrials.gov
    ALN-5288 DRUG Phase PHASE1 Alzheimer's Disease ClinicalTrials.gov
    Standard of Care OTHER Preclinical Hereditary Amyloidosis, Transthyretin-Related ClinicalTrials.gov
    ALN-AGT01 DRUG Phase PHASE2 Hypertension ClinicalTrials.gov
    ALN-4285 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    ALN-APP DRUG Phase PHASE2 Cerebral Amyloid Angiopathy ClinicalTrials.gov
    ALN-TTRSC04 DRUG Phase PHASE1 Transthyretin-Mediated Amyloidosis ClinicalTrials.gov
    Olmesartan DRUG Phase PHASE2 Hypertension ClinicalTrials.gov
    Amlodipine DRUG Phase PHASE2 Hypertension ClinicalTrials.gov
    Indapamide DRUG Phase PHASE2 Hypertension ClinicalTrials.gov
    ALN-AGT01 RVR DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Computer algorithm for ATTR DEVICE Phase EARLY_PHASE1 Transthyretin Amyloidosis ClinicalTrials.gov
    ALN-RSV01 DRUG Phase PHASE2 Respiratory Syncytial Virus Infections ClinicalTrials.gov
    ALN-TTR01 DRUG Phase PHASE1 Transthyretin Mediated Amyloidosis (ATTR) ClinicalTrials.gov
    ALN-VSP02 DRUG Phase PHASE1 Solid Tumors ClinicalTrials.gov
    ALN-PCS02 DRUG Phase PHASE1 Elevated LDL-Cholesterol (LDL-C) ClinicalTrials.gov
    ALN-TTR02 DRUG Phase PHASE1 TTR-mediated Amyloidosis ClinicalTrials.gov
    ALN-PCSSC DRUG Phase PHASE1 Hypercholesterolemia ClinicalTrials.gov
    ALN-TTRSC (revusiran) DRUG Phase PHASE1 TTR-mediated Amyloidosis ClinicalTrials.gov
    patisiran (ALN-TTR02) DRUG Phase PHASE1 Transthyretin (TTR)-Mediated Amyloidosis ClinicalTrials.gov
    Revusiran (ALN-TTRSC) DRUG Phase PHASE3 Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) ClinicalTrials.gov
    Normal Saline DRUG Phase PHASE2 Respiratory Syncytial Virus Infections ClinicalTrials.gov
    ALN-TTRSC02 DRUG Phase PHASE1 Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) ClinicalTrials.gov
    ALN-HBV DRUG Phase PHASE1 Hepatitis B ClinicalTrials.gov
    givosiran (ALN-AS1) DRUG Phase PHASE1 Acute Intermittent Porphyria ClinicalTrials.gov
    Cemdisiran DRUG Phase PHASE2 Atypical Hemolytic Uremic Syndrome ClinicalTrials.gov
    Lumasiran DRUG Phase PHASE1 Primary Hyperoxaluria Type 1 (PH1) ClinicalTrials.gov
    ALN-CC5 DRUG Phase PHASE1 Paroxysmal Nocturnal Hemoglobinuria (PNH) ClinicalTrials.gov
    Revusiran DRUG Phase PHASE2 Transthyretin (TTR)-Mediated Amyloidosis ClinicalTrials.gov
    5-probe cocktail DRUG Phase PHASE1 Acute Intermittent Porphyria (AIP) ClinicalTrials.gov
    Givosiran DRUG Phase PHASE1 Acute Intermittent Porphyria (AIP) ClinicalTrials.gov
    ALN-AAT DRUG Phase PHASE1 Antitrypsin Deficiency Liver Disease ClinicalTrials.gov
    Placebos DRUG Phase PHASE2 Atypical Hemolytic Uremic Syndrome ClinicalTrials.gov
    ALN-AAT02 DRUG Phase PHASE1 ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease ClinicalTrials.gov
    Irbesartan-Matching Placebo DRUG Phase PHASE1 Hypertension ClinicalTrials.gov
    Irbesartan DRUG Phase PHASE1 Hypertension ClinicalTrials.gov
    ALN-AGT01-Matching Placebo DRUG Phase PHASE1 Hypertension ClinicalTrials.gov
    No intervention. Retrospective observation only. OTHER Preclinical Chronic Inflammatory Demyelinating Polyneuropathy ClinicalTrials.gov
    ALN-TTRSC (revusiran) for subcutaneous administration DRUG Phase PHASE2 TTR-mediated Amyloidosis ClinicalTrials.gov
    0.9% Sodium Chloride (placebo) DRUG Phase PHASE2 Haemodialysis ClinicalTrials.gov
    ALN-HSD DRUG Phase PHASE1 Nonalcoholic Steatohepatitis ClinicalTrials.gov
    ALN-TTR02 (patisiran) administered by intravenous (IV) infusion DRUG Phase PHASE2 TTR-mediated Amyloidosis ClinicalTrials.gov
    ALN-XDH DRUG Phase PHASE1 Gout ClinicalTrials.gov
    ALN-KHK DRUG Phase PHASE1 Type 2 Diabetes Mellitus (T2DM) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Alnylam Pharmaceuticals Inc
    • Ticker Symbol: ALNY

Search

News categories